A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis

British Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 129-138

  Cohen, Stanley ^a   Emery, Paul ^b,c   Greenwald, Maria ^d   Yin, Donghua ^e   Becker, Jean Claude ^e   Melia, Lisa Ann ^e   Li, Ruifeng ^e   Gumbiner, Barry ^e   Thomas, Dolca ^e   Spencer Green, George ^e   Meng, Xu ^e  

^a METROPLEX CLINICAL RESEARCH CENTER   (United States)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^d Desert Medical Advances   (United States)

^e PFIZER INC   (United States)

Author keywords

biosimilar; CD19+ B cell counts; immunogenicity; pharmacokinetics; rituximab; safety

Indexed keywords

BIOSIMILAR AGENT; CD19 ANTIGEN; METHOTREXATE; PF 05280586; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTHROPATHY; ARTICLE; AUTOMUTILATION; BACTERIAL ARTHRITIS; BIOEQUIVALENCE; BONE CANCER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; EUROPEAN UNION; FEMALE; HEART ATRIUM FLUTTER; HUMAN; IMMUNOGENICITY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERICARDITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; THROMBOCYTOPENIC PURPURA; UNITED STATES;

EID: 84976531244     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12916     Document Type: Article

References (12)

1. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical Issues. Draft [online]. London, UK: European Medicines Agency (EMEA); 2013. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144124.pdf (last accessed 16 September 2015).
2. Health Canada. Guidance for sponsors: information and submission requirements for subsequent entry biologics (SEBs) [online]. Ottawa, Ontario: Health Canada Health Products and Food Branch, Minister of Public Works and Government Services; 2008. Available at http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb-pbu-2010-eng.pdf (last accessed 16 September 2015).
3. US Food and Drug Administration, US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. Draft guidelines [online]. Rockville, MD: (CBER); 2012. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf (last accessed 16 September 2015).
4. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs) [online]. Geneva, Switzerland: World Health Organization; 2009. Available at http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf (last accessed 16 September 2015).
5. Genentech Inc. Rituxan® (rituximab) prescribing information [online]. South San Francisco, CA, 2013. Available at http://www.gene.com/download/pdf/rituxan_prescribing.pdf (last accessed 7 October 2014).
6. F. Hoffmann-La Roche Ltd. MabThera (rituximab) Summary of product characteristics [online]. Basel, Switzerland; 2008. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf (last accessed 7 October 2014).
7. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012; 51 (Suppl. 5): v3–11.
8. Karnik S, Thompson MS, DeGruttola H, Ferrari S, Gu L, Aggarwal P, Porter TJ, Rouse JC, Ng C-K. Characterization and comparison of PF-05280586, a proposed rituximab biosimilar, to the licensed product. Proceedings of the American Association of Pharmaceutical Scientists – 2013 National Biotechnology Conference (APS-NBC 2013); 20–22 May, 2013; San Diego, CA, USA.
9. Yin D, Becker J-C, Melia L, Li R, Gumbiner B, Thomas D, Spencer-Green G, Meng X. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in subjects with active rheumatoid arthritis (REFLECTIONS B328-01). Ann Rheum Dis 2014; 73: FRI0309.
10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569–81.
11. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498–502.
12. Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, Davies BE. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007; 47: 1119–28.